SEC 13F Intelligence

Managers / Q1 2020 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$1.5B
Q1 2020
Positions
62
Filings on Record
27
2019–present window
Filed
May 15, 2020
original filing

Summary

Boxer Capital, LLC reported $1.5B in U.S.-listed holdings across 62 positions for Q1 2020.

Its largest position, Mirati Therapeutics, represents 9.3% of the portfolio.

Compared with Q4 2019, the fund opened 19 new positions and exited 8.

Portfolio Metrics

Turnover
+24.3%
vs prior filed quarter
Top-10 Concentration
+53.5%
share of reported value
Largest Position
+9.3%
Mirati Therapeutics
New / Exited
19 / 8
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2.2BQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 73.3%Other: 15.8%ADR: 9.7%ETP: 1.2%
  • Common Stock · 73.3% · $1.1B
  • Other · 15.8% · $231M
  • ADR · 9.7% · $143M
  • ETP · 1.2% · $18M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
RVMDREVOLUTION MEDICINES INCNEW+3.05M3.05M+$67M$67M
REGNREGENERON PHARMACEUTICALSNEW+135.0K135.0K+$66M$66M
BDTXBLACK DIAMOND THERAPEUTICS INEW+2.01M2.01M+$50M$50M
PASSAGE BIO INCNEW+1.88M1.88M+$30M$30M
COMPUGEN LTDNEW+2.38M2.38M+$17M$17M
TREURTRILLIUM THERAPEUTICS INCNEW+4.08M4.08M+$16M$16M
ACADACADIA PHARMACEUTICALS INCNEW+370.0K370.0K+$16M$16M
BARCLAYS BK PLCNEW+300.0K300.0K+$14M$14M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2020

61 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MIRATI THERAPEUTICS INCCOM9.25%$136M1.77M
2IMMUIMMUNOMEDICS INChistory →COM7.76%$114M8.45M
3ONCBEIGENE LTDhistory →SPONSORED ADR7.76%$114M925.0K
4ODONATE THERAPEUTICS INCCOM6.33%$93M3.36M
5RVMDREVOLUTION MEDICINES INChistory →COM4.55%$67M3.05M
6REGNREGENERON PHARMACEUTICALShistory →COM4.49%$66M135.0K
7SPRINGWORKS THERAPEUTICS INCCOM3.82%$56M2.08M
8BDTXBLACK DIAMOND THERAPEUTICS Ihistory →COM3.43%$50M2.01M
9SEATTLE GENETICS INCCOM3.15%$46M400.0K
10SAGE THERAPEUTICS INCCOM3.00%$44M1.53M
11RCUSARCUS BIOSCIENCES INChistory →COM2.92%$43M3.08M
12QUREUNIQURE NVhistory →SHS2.48%$36M765.4K
13ESPRESPERION THERAPEUTICS INC NEhistory →COM2.10%$31M975.0K
14ALLAKOS INCCOM2.05%$30M675.0K
15PASSAGE BIO INCCOM2.02%$30M1.88M
16ATRECA INCCL A COM1.96%$29M1.73M
17DBV TECHNOLOGIES S ASPONSORED ADR1.88%$28M7.03M
18ARGXARGENX SEhistory →SPONSORED ADR1.80%$26M200.0K
19KDMNKADMON HLDGS INChistory →COM1.77%$26M6.21M
20GOSSGOSSAMER BIO INChistory →COM1.51%$22M2.19M
21AMICUS THERAPEUTICS INCCOM1.46%$21M2.33M
22BMRNBIOMARIN PHARMACEUTICAL INChistory →COM1.44%$21M250.0K
23RCKTROCKET PHARMACEUTICALS INChistory →COM1.39%$20M1.47M
24ANABANAPTYSBIO INChistory →COM1.25%$18M1.30M
25BLUBELLUS HEALTH INC NEWhistory →COM NEW1.21%$18M1.77M
26DIREXION SHS ETF TRDAILY S&P BIOTEC1.20%$18M1.25M
27COMPUGEN LTDORD1.18%$17M2.38M
28TREURTRILLIUM THERAPEUTICS INChistory →COM NEW1.12%$16M4.08M
29ACADACADIA PHARMACEUTICALS INChistory →COM1.07%$16M370.0K
30PREVAIL THERAPEUTICS INCCOM0.93%$14M1.12M
31GLOBAL BLOOD THERAPEUTICS INCOM0.87%$13M250.0K
32NEOLEUKIN THERAPEUTICS INCCOM0.78%$11M1.01M
33CABACABALETTA BIO INChistory →COM0.78%$11M1.57M
34RLMDRELMADA THERAPEUTICS INChistory →COM0.70%$10M300.0K
35AGENUS INCCOM NEW0.67%$10M4.00M
36MARINUS PHARMACEUTICALS INCCOM0.66%$10M4.80M
37AMARIN CORP PLCSPONS ADR NEW0.61%$9M2.25M
38AKROAKERO THERAPEUTICS INCCOM0.60%$9M416.5K
39AXSMAXSOME THERAPEUTICS INCCOM0.60%$9M150.0K
40KURAKURA ONCOLOGY INCCOM0.57%$8M844.8K
41SNDXSYNDAX PHARMACEUTICALS INCCOM0.54%$8M725.8K
42SELECTA BIOSCIENCES INCCOM0.54%$8M3.28M
43KODKODIAK SCIENCES INCCOM0.49%$7M150.0K
44MATINAS BIOPHARMA HLDGS INCCOM0.47%$7M11.48M
45XENEXENON PHARMACEUTICALS INCCOM0.46%$7M600.0K
46MEI PHARMA INCCOM NEW0.32%$5M2.91M
47ARTARA THERAPEUTICS INCCOM0.31%$5M199.6K
48KINIKSA PHARMACEUTICALS LTDCOM CL A0.31%$4M290.6K
49MIRMMIRUM PHARMACEUTICALS INCCOM0.30%$4M317.0K
50ZOGENIX INCCOM NEW0.29%$4M175.0K
51LJPCLA JOLLA PHARMACEUTICAL COCOM PAR $.0001 20.25%$4M890.7K
52SOLID BIOSCIENCES INCCOM0.25%$4M1.53M
53BARCLAYS BK PLCSHRT TRM ETN 480.24%$3M75.0K
54IDYAIDEAYA BIOSCIENCES INCCOM0.21%$3M764.3K
55LIFESCI ACQUISITION CORPUNIT 03/31/20250.20%$3M300.0K
56CYMABAY THERAPEUTICS INCCOM0.20%$3M2.00M
57MREOMEREO BIOPHARMA GROUP PLCADS0.17%$3M2.45M
58MISTMILESTONE PHARMACEUTICALS INCOM0.14%$2M1.10M
59CELLECTAR BIOSCIENCES INCCOM PAR0.08%$1M920.0K
60BELLEROPHON THERAPEUTICS INCCOM0.07%$1M98.8K
61ZYMEWORKS INCCOM0.06%$887,00025.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2.2B79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.